Insight Medbotics joins NVIDIA Inception

August 27, 2025

Insight Medbotics, an interventional oncology company advancing precision in cancer care through its MRI-compatible robotics, is pleased to announce that it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.

While MRI is the gold standard for visualizing soft-tissue cancers and is commonly used for diagnostic scans, this imaging technology isn’t widely used to perform cancer interventions, such as taking biopsies or in other treatments. Insight Medbotics envisions development in other biopsies, therapy delivery, and device placement, and is developing a new robotics category designed for use with MRI to help solve this access challenge.

The company’s IGAR system has been clinically demonstrated in breast cancer patients and is the world’s first and only FDA-cleared, MRI-compatible robot (breast biopsy). Prostate cancer, which still relies on imprecise biopsy methodologies and radical whole gland treatment, is the next patient care area where the IGAR robotics technology could play a leading role in delivering greater precision, better economics, and an improved patient experience.

“Participating in the NVIDIA Inception program will help us to access a global network of investors who understand the robotics market as we advance our MRI-compatible robotics technology to market,” says Fazila Seker, CEO and member of the Insight Medbotics Board of Directors. “Our approach integrates hardware and the digitization of an entire care pathway, which may offer new data-driven clinical insight in ways that haven’t been possible before. Participating in the program will also give our team opportunities to collaborate with NVIDIA’s industry-leading robotics experts and other AI-driven organizations in their ecosystem.”

NVIDIA Inception helps startups during critical stages of product development, prototyping and deployment. Every Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow.

About Insight Medbotics

Insight Medbotics is an interventional oncology company advancing precision in cancer care through its MRI-compatible robotics. IGAR, the company’s flagship MRI-compatible robot, has been clinically demonstrated. As the only company to receive a FDA 510(k) clearance for use of a robot with an MRI, Insight Medbotics is now advancing the technology to improve the standard of precision in prostate cancer care.